Grants for Public Housing Authorities

This grant provides funding and protected time for U.S. postdoctoral researchers and junior faculty to conduct mentored research in low- and middle-income countries, focusing on global health priorities.

This funding opportunity supports interdisciplinary research teams in the U.S. working to tackle critical issues at the intersection of HIV and substance use disorders, with a focus on prevention, understanding, and treatment strategies.

The Office of Planning, Research and Evaluation (OPRE), within the Department of Health and Human Services' (HHS) Administration for Children and Families (ACF), plans to solicit applications for cooperative agreements under the Child Care and Development Fund (CCDF) Lead Agency Data and Research Capacity: Planning Grants (Phase I). These projects are meant to support partnerships between CCDF Lead Agencies and researchers to develop and improve state, territory, and Tribal data systems and build the capacity of CCDF Lead Agencies to collect, analyze, and use data to guide child care policy decisions and program improvement efforts. Sponsored projects will work in collaboration to: (1) assess the current data and research capacity of the CCDF Lead Agency; (2) develop questions of interest to investigate state, territory, and Tribal child care policies and practices; (3) develop logic models to identify the data needed to address the questions of interest; (4) identify data sources available to answer questions of interest and assess the accessibility of those data; (5) identify possible data sources from other state, territory, Tribal, and local data systems for linking; (6) determine whether there is a need to collect data to answer policy-relevant questions; and (7) address the barriers to collecting, analyzing, and using data to inform child care policy decisions. These projects are intended to build the capacity of CCDF Lead Agencies to use data, including data on children, families, the workforce, and providers that participate in the child care subsidy system, to make data-informed decisions to improve child care policies and practices. These 18-month projects, with one project and budget period, will fund a planning phase to develop a research plan to address questions of interest to the CCDF Lead Agency, including a plan for identifying, linking, and using state, territory, and Tribal data to inform child care policy decisions. These planning projects may be followed by a second competition (Phase II), under a separate Notice of Funding Opportunity, to support execution of the research plans to develop and improve state, territory, and Tribal data systems. Projects must be conducted through partnerships between CCDF Lead Agencies (i.e., states, territories, Tribes, or local subsidy administering agencies) and researchers from institutions of higher education, within the state agency, research organizations, and/or other organizations with proven expertise conducting policy research. Applications are invited from CCDF Lead Agencies, institutions of higher education, research organizations, and other organizations with proven expertise conducting policy research. The research supported by this program should be collaborative from start to finish. The CCDF Lead Agency and their research partners must work together to assess the current data and research capacity of the CCDF Lead Agency and develop a feasible plan for identifying, linking, and using data to address questions of relevance to the CCDF Lead Agency. Sponsored projects will be expected to participate in a Consortium that will meet and communicate regularly to identify opportunities for coordination, such as to share information on facilitators and barriers to identifying and using data to inform child care policies and methods for linking data across systems, and to develop collective expertise and resources for the field. The Consortiums collaboration will support research capacity and learning within individual projects and across award recipients. Funding is subject to availability of funds and the best interests of the federal government.

The Unaccompanied Children Lived Experience and Youth Engagement Support Program is forecasted to provide funding to establish, manage, and evaluate a Lived Experience Community Council and Lived Experience Leadership Academy comprised of former unaccompanied children and individuals who sponsored children from ORR care. The recipient shall recruit, identify, orient, and train lived experience experts that reflect the demographic diversity (e.g., age, language, etc.) and varied experiences and circumstances (e.g., pregnant/parenting youth, survivors of human trafficking, etc.) of former unaccompanied children and sponsors. Therefore, prior experience developing programming centering lived experience and youth voice and/or supporting unaccompanied children, sponsors, and reunified families is highly desirable. These lived experience bodies have two objectives. The first is to collect feedback from former unaccompanied children and reunified families about their first-hand experience integrating to the United States. The second is to positively impact the lives of Community Council and Leadership Academy members by building their capacity to serve as leaders within their respective communities. The recipient shall provide the necessary resources, such as personnel, to support the implementation of the lived experience bodies. Task areas will include: a) development of the Community Council implementation plan and Leadership Academy curriculum; b) development of a web-based application; c) selection of eligible candidates to the appropriate lived experience body; d) project management; e) interpretation and translation services for, and during, community meetings; f) secure technology for members to participate in virtual meetings; g) compensate members for their time; h) as separate cohorts, coordinate and implement Washington Weeks for the Community Council and Leadership Academy to meet with government leaders and relevant stakeholders, and i) disseminate to the ORR-funded network feedback obtained through the lived experience bodies' work that centers youth voice and lived experience.

This Notice of Funding Opportunity (NOFO) invites applications for sites to participate in the Genomic Medicine eConsult Research Network, hereafter referred to as the eConsult Network. The eConsult Network will consist of 2-3 sites working with NHGRI to conduct research on the impact of and methods for implementing regional clinician-to-clinician genomic medicine eConsult services. Specifically, sites will be funded to research how to best design, develop, and implement regional genomic medicine eConsult services; provide outreach to potential users, including those at underserved settings; and assess the impact on key stakeholders while developing successful implementation strategies and resources that can be broadly shared and adopted.

This funding opportunity supports high-risk, multi-center observational studies aimed at advancing research on diabetes, digestive diseases, kidney disorders, and other related health conditions, encouraging diverse institutions to collaborate and innovate.

This funding opportunity supports high-risk, multi-center clinical trials aimed at addressing significant health issues related to diabetes, digestive diseases, and kidney disorders, encouraging diverse institutions to apply for impactful research that can transform clinical practices.

This funding opportunity supports researchers in planning high-risk, multi-center clinical studies focused on kidney, digestive, diabetes, and metabolic disorders, helping them develop essential protocols and administrative frameworks before conducting the actual trials.

This funding opportunity supports institutions in developing clinician scientists through structured research training in substance use and addiction, enabling them to pursue independent research careers.

This funding opportunity supports researchers and institutions conducting clinical trials and studies to improve stroke treatment, recovery, and prevention through collaboration within a national network.

This funding opportunity supports early stage researchers in pursuing innovative and high-risk scientific projects that significantly diverge from their previous work, without the need for preliminary data.

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Clinical Network Hub (HUB). The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

The National Cancer Institute (NCI) intends to issue the U54 Specialized Programs of Research Excellence in Cancer Health Disparities and Minority Health (CHD-MH SPORE) notice of funding opportunity (NOFO). The program will support a network of multidisciplinary, multi-institutional U54 CHD-MH SPOREs, which are multi-project awards uniquely focused on health disparities and/or minority health translational research for improved prevention, early detection, diagnosis, and treatment of cancer in populations who are underserved. U54 CHD-MH SPOREs can investigate more than one cancer type in underserved populations, including groups of highly related cancers (e.g., gastrointestinal or head and neck). The research supported through this program must be translational and must stem from research on human biology, addressing the interplay of various determinants of health with the biology of the disease. U54 CHD-MH SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant, which may include a clinical trial. This Notice of Intent to Publish is being provided to allow sufficient time for applicants to develop strong applications. The NOFO is expected to be published in late winter 2024 with only one expected application due date in late September 2024.

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-related Dementias (ADRD) Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. Brain health equity is the fair distribution of brain health determinants, outcomes, and resources within and between segments of the population, regardless of social standing. Measures and methods of interest will test outcomes and mechanisms of action in settings customized for individuals with different needs and linked to real-world function. Applications must explain how the platform will meet evolving community needs and partner with other NIA-funded programs. Applications must also describe activities that will achieve the following objectives: Develop an organizational and governance structure to support the administration, innovation, and dissemination functions of the Network. Propose activities to establish a framework that will facilitate the development of innovative strategies for standardization and use of methods and measures across NIA-supported projects and support activities for the discovery and development of innovative and novel measures and data. Disseminate Network resources and products to the broader AD/ADRD research community. Ensure that all measures and methods development and validation occurs in a racially, ethnically, geographically, and diagnostically diverse set of participants, including members of NIH-defined Health Disparity Populations. This also includes establishing the acceptability and feasibility of using the proposed instruments in both cognitively normal individuals and persons living with cognitive impairment (PLWCI), including subjective cognitive decline. NIA is particularly interested in proposals that advance equity for populations disproportionately impacted by AD/ADRD. For example, Black and Hispanic Americans have a higher prevalence of AD/ADRD compared to non-Hispanic White Americans. Resources, including measurement instruments, methods, algorithms, code, documentation, and normative data will enable other, future measures and methods development projects that support AD/ADRD primary prevention research needs. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in early 2024 with an expected application due date in Spring/Summer 2024. This NOFO will utilize the U24 activity code.

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Coordinating Center (TNCC). The TrialNet network identifies people with type 1 diabetes (T1D) at stages before and after onset of clinical symptoms and enrolls them in trials and studies aimed at prevention of progression to clinical disease and preservation of insulin production. The TNCC participates in ongoing studies and intervention trials as well as the design and conduct of new studies and intervention trials. The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination and public accessibility. The TNCC will be responsible for network administration and operations, including the evaluation, selection, and funding (through subcontracts) of Clinical Centers and central support units (such as laboratories) necessary for the conduct of TrialNets clinical studies. The TNCC PD/PI will be a voting member of the TrialNet Executive and Steering Committees, contributing to network leadership. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

This grant provides funding for early stage investigators to pursue innovative and high-risk research projects involving human participants, without the need for preliminary data.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports researchers conducting fully remote clinical trials to evaluate the effectiveness of complementary and integrative health interventions, utilizing mobile health technologies without any in-person contact.

HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance. The goal of this initiative is to support research aimed at (1) identification of targets and pathways by which transcriptional activity of HIV can be suppressed in HIV reservoirs including the CNS in people with SUD, and (2) application of emerging small molecule drug discovery approaches to identify novel compounds that can be utilized as pharmacological probes and as drugs to suppress HIV transcription in people with HIV-SUD comorbidity.

This funding opportunity supports researchers conducting feasibility trials of mind and body interventions for high-priority health conditions, aiming to gather essential data for future large-scale clinical studies.